When accredited investors research secondary transfers, the right of first refusal (ROFR) absorbs most of the attention. ROFR is real and worth understanding. But there is a second, often more consequential restriction that sits alongside ROFR in most shareholder agreements: the company's affirmative consent right over any transfer.

Unlike ROFR — which gives the company the option to repurchase at the agreed price — consent rights give the company the ability to simply say no. No repurchase. No compensation. No obligation to explain the decision. The transfer does not happen, and the buyer must return capital that has been sitting in escrow for weeks.

Understanding the difference between these two mechanisms, and knowing which one is more likely to apply in a given transaction, is foundational due diligence for any secondary buyer.

ROFR vs. consent: the structural difference

Right of First Refusal (ROFR)
The company (or its designee, often existing investors) has the right to purchase shares at the price offered in a secondary transaction before an outside buyer can complete the transfer. If the company declines to exercise ROFR, the transfer typically proceeds — subject to any remaining consent requirements.
Transfer Consent Right
A separate provision requiring the company's board or management to affirmatively approve any secondary transfer. The company does not have to purchase the shares; it simply has the right to veto the transfer. Some agreements require 'reasonable' consent; others grant full discretion.
Right of First Offer (ROFO)
A less common variant requiring the seller to offer the company or other parties the right to bid before soliciting third parties. Different from ROFR in that it triggers before a price is set, not after.

In practice, many shareholder agreements contain both: ROFR comes first, and if the company waives it, a separate consent step follows. Some agreements collapse these into a single process; others treat them as sequential hurdles. The specific language in the investor rights agreement — or, for employee shareholders, the equity plan documents and option agreement — controls.

Why companies use consent rights

A company's interest in controlling its cap table is legitimate. Management teams care about who owns their equity for several reasons: competitive intelligence concerns (a direct competitor holding shares could gain information rights), regulatory sensitivities (foreign ownership rules, CFIUS review thresholds), and internal cap table hygiene that matters when approaching an IPO or acquisition.

Some companies use consent rights narrowly — they approve most transfers from known platforms and institutional sellers, and only block transactions that raise genuine strategic concerns. Other companies use consent rights aggressively, particularly during periods of internal sensitivity such as the months before a fundraising round closes, during an IPO quiet period, or when secondary pricing is well above or below where the company wants the market to sit.

A company blocking a secondary transfer does not mean the company is in trouble. It often means the opposite — that the company cares about who holds its equity and is actively managing that process. But the economic outcome for a blocked buyer is the same either way: no position, no return.

There is also a timing dimension. Companies that are preparing for a tender offer sometimes quietly tighten consent approvals in the open secondary market — not through any public announcement, but simply by declining transfers — to channel liquidity through the controlled tender process instead. Buyers active in the secondary market around names like those on our platform sometimes encounter this pattern without understanding its cause.

What discretionary vs. reasonable consent means for you

The single most important variable in a consent clause is whether the company's consent must be 'reasonable' or can be withheld in its 'sole discretion.' These are very different standards.

  • 'Sole discretion' means the company can say no for any reason or no reason. There is no legal recourse for a blocked buyer as long as the process was followed correctly. This is the more common formulation in founder-controlled companies and later-stage preferred equity agreements.
  • 'Reasonable' or 'not to be unreasonably withheld' creates at least a theoretical basis for a buyer or seller to challenge a denial if it was arbitrary or pretextual. In practice, litigation over a withheld secondary consent is exceedingly rare — the cost and complexity almost never justify it.
  • Some agreements are silent on the standard, which courts have generally interpreted as permitting broad discretion. Silence is not protection.

How to manage consent risk before you commit capital

The best mitigation is process discipline before you sign, not legal remedies after a denial. Here is what that looks like in practice.

  1. Ask the platform whether they initiate a consent inquiry with the company prior to executing a buyer agreement. Some platforms do; many do not. Platforms that run consent and ROFR in parallel with the execution process reduce your exposure to late-stage fall-through significantly.
  2. Confirm the escrow terms: if the company denies consent, when does your capital return to you, and does it accrue any return during the hold? Most escrow arrangements return capital promptly, but the timeline should be explicit.
  3. Ask the platform whether they have completed prior transfers in the same issuer. A track record of completed transactions is the best available proxy for whether consent is routinely granted. It is not a guarantee.
  4. Understand what the seller's agreement says. Sometimes the buyer's platform cannot share the full underlying agreement, but they should be able to tell you whether consent is required and at what level — board, management, or specific officer.
  5. Do not concentrate capital in a single indication that depends on a single consent decision. If you want meaningful exposure to a name, consider splitting across separate indications or vehicles to reduce single-event fall-through risk.

SPV structures and consent: an added layer

When you buy into a secondary transaction via a special purpose vehicle (SPV), the consent mechanics work slightly differently. The SPV itself is the buyer of the underlying shares, not you as an individual investor. This means the consent decision is made about the SPV entity and its general partner — not about you personally.

This has a practical implication: an experienced, recognized SPV manager with a track record of completed transfers at a given company may have a meaningfully easier time obtaining consent than an individual buyer presenting directly. Companies sometimes maintain informal approved-transfer-agent lists. If your platform's SPV structure is not on that list — or if the GP is unfamiliar to the company — consent may be slower or less certain.

Conversely, a direct transfer from a selling employee to you as an individual accredited investor may require a more extensive review process, because the company is vetting an individual rather than an established entity. Neither path is automatically superior — the company's preferences vary by issuer.

What happens when consent is denied

If a transfer is denied, the transaction unwinds. The seller retains their shares. Your capital returns from escrow. You have no position. You may have also spent several weeks in the process, during which you were unable to deploy that capital elsewhere.

There is no secondary market for secondary market fall-throughs. The opportunity cost is real, and it is asymmetric: you bear it, not the company and not the platform.

This is precisely why the upfront process matters. Platforms that confirm seller-side supply and initiate consent and ROFR clearance before you are asked to commit capital reduce your exposure to this outcome materially. It is worth asking directly before you place an indication.

For a closer look at how ROFR waiver timelines interact with liquidity needs — particularly when you are working against a deadline — see our guide on managing ROFR waiver timelines. For a full breakdown of what your transfer agreement should contain before you sign, visit the transfer policy explainer in our resources section.